1. Please check and comment entries here.
Table of Contents

    Topic review

    Biofluids in Haematological Malignancies

    Subjects: Hematology
    View times: 5
    Submitted by: Katie Dunphy

    Definition

    The proteomes of biofluids, including serum, saliva, cerebrospinal fluid, and urine, are highly dynamic with protein abundance fluctuating depending on the physiological and/or pathophysiological context. Improvements in mass-spectrometric technologies have facilitated the in-depth characterisation of biofluid proteomes which are now considered hosts of a wide array of clinically relevant biomarkers. Promising efforts are being made in the field of biomarker diagnostics for haematologic malignancies. Several serum and urine-based biomarkers such as free light chains, β-microglobulin, and lactate dehydrogenase are quantified as part of the clinical assessment of haematological malignancies. However, novel, minimally invasive proteomic markers are required to aid diagnosis and prognosis and to monitor therapeutic response and minimal residual disease.

    1. Introduction

    Advances in proteomic technologies, protocols, and bioinformatic pipelines in recent decades have led to substantial progress in understanding the molecular phenotype of organisms by providing mechanistic insights into a wide range of cellular processes. Clinical proteomics aims to translate these discoveries to the clinic for the improvement of patient care. A major goal for many researchers in the biomedical community is the discovery of highly sensitive biomarkers to aid diagnosis, prognosis, and the monitoring of disease progression. Analysing changes in the proteome of physiologically or pathologically distinct samples (differential proteomics) enables researchers to identify proteins that are associated with different disease states [1]. Furthermore, the use of quantitative proteomic protocols, such as mass spectrometry-based techniques for discovery and targeted analyses, facilitates the quantitation of these proteins to identify candidate biomarkers with altered abundances for potential clinical applications [2]. Detecting and quantifying these protein markers in patient samples can contribute to an earlier diagnosis, a more accurate prognosis, and/or identifying therapeutic regimens that are more likely to benefit individual patients. Biofluids, such as serum, plasma, saliva, cerebrospinal fluid (CSF), urine, and bone marrow-conditioned media, are often considered reflections of a tumours’ molecular make-up, possessing genomic, transcriptomic, and proteomic indicators of disease (Figure 1). They represent a less invasive, less expensive, and more reproducible means of detecting disease-associated biomarkers when compared to invasive tissue biopsies (Table 1) [3].
    Figure 1. Biofluids are easily accessible and suitable for proteomic analysis in a clinical setting. Red font indicates promising protein biomarkers in haematological malignancies identified in the corresponding biofluid. CXCL13, C-X-C motif chemokine ligand 13; IL-10, interleukin 10; S100A8/A9, S100 calcium-binding protein A8/A9; FABP5, fatty acid binding protein 5; 2-HG, 2-hydroxyglutarate; NGAL, neutrophil gelatinase-associated lipocalin; BDNF, brain-derived neurotrophic factor. Created using BioRender.
    Table 1. Advantages and disadvantages of tissue and biofluid-based proteomics for the detection of blood cancer-associated biomarkers.
    Tissue-Based Proteomics Biofluid-Based Proteomics
    Advantages Disadvantages Advantages Disadvantages
    Direct analysis of proteins from site of disease Invasive procedure Non-invasive Not in direct proximity to the site of disease
    Facilitates the study of the bone marrow microenvironment Localised sampling bias due to heterogeneity of the bone marrow microenvironment Ease of longitudinal sampling High abundance proteins can hamper detection
    Gold standard for diagnostic and prognostic applications High cost Low cost  
    Bone marrow biopsies can be painful procedures Reflective of disease state  
    Haematological malignancies are characterised as cancers that develop in the bone marrow, lymph nodes, and/or the blood from cells of the haematopoietic lineage. These malignancies include leukemias such as acute myeloid and chronic myeloid leukaemia, lymphomas such as Hodgkin’s lymphoma, and multiple myeloma (MM). The discouraging five-year survival rate, high rate of relapse, and incurability of certain blood cancer subtypes emphasises the need to identify novel therapeutic targets and biomarkers for the early detection of relapse and to assess disease progression following treatment.

    2. Blood

    Serum and plasma are often spoken about synonymously as they only differ from one another by the presence or absence of clotting agents [4]. Serum is retrieved following blood coagulation and centrifugation to remove fibrin clots, blood cells, and platelets. Plasma is prevented from clotting by adding an anti-coagulant, such as ethylenediaminetetraacetic acid (EDTA) or heparin, prior to extraction [5]. Despite the minor differences in composition, several studies have suggested that use of the incorrect sample source can lead to an improper diagnosis, hence why often either serum or plasma are preferred for certain assays [6][7][8]. Due to alterations in glucose levels between serum and plasma, serum is not recommended as a medium for the diagnosis of diabetes [9]. In addition, serum is the preferred sample source for quantitation of complement activation as EDTA-treated plasma must be transferred to veronal-buffered saline containing Ca2+ and Mg2+ to enable complement activation, and lepirudin as an EDTA replacement, prior to analysis [10].

    2.1. Complexity of the Serum/Plasma Proteome

    The high potential of serum/plasma as sources for protein biomarker discovery lies in their close proximity to all tissues, making their proteomic profiles reflective of the overall state of the organism [4][11]. An advantage of using serum or plasma for proteomic analysis is the minimally invasive, low-risk method of sample collection, which also facilitates sequential testing during the course of a disease. Despite the benefit of a high protein content, characterising the serum/plasma proteome can be challenging due to the nine-fold dynamic protein concentration range with just over 20 proteins including albumin, transferrin’s, immunoglobulins, and apolipoproteins, making up ≈99% of the serum/plasma proteome. The remaining 1% contains many low-abundant circulatory and secreted proteins that are often of more interest in research and as potential disease-associated biomarkers [12][13][14].

    2.2. Methods for Analysing the Serum/Plasma Proteome

    Several techniques have been employed to counteract the challenges of analysing such a dynamic and complex proteome. In order low abundance proteins to be effectively analysed, high-abundance protein (HAP) depletion, enrichment of specific low abundance proteins (LAPs), or fractionation to reduce sample complexity are often performed [15] (Figure 2). The removal of high-abundance proteins is necessary as they typically dominate the detection signals of analytical techniques, leaving low abundance proteins less likely to be detected and quantified [4][16]
    Figure 2. Schematic illustrating the steps involved in the detection of protein biomarkers in biofluids and their applications in a clinical setting. HAP, high-abundance protein; LAP, low-abundance protein; CTC, circulating tumour cell; ELISA, enzyme-linked immunosorbent assay; EpCAM, epithelial cell adhesion molecule; CK, cytokeratin. * Dynamic range of corresponding biofluid. Created using BioRender.

    2.3. Detecting Biomarkers in Serum and Plasma

    In addition to proteins, plasma, and serum are home to a diverse range of cells and other macromolecules including circulating tumour cells (CTCs), circulating tumour nucleic acids (ctNAs), and tumour-derived extracellular vesicles, namely, exosomes, which have been shed from tumours and their metastatic sites [17][18][19]. Detection of abnormal concentrations of these macromolecules in plasma/serum may lead to cancers being diagnosed at an earlier stage, facilitating a more accurate prognosis and improved chance of patient survival [3]. Other reviews on liquid biopsies have focused on the evaluation of circulating free nucleic acids in haematological malignancies [20].

    2.4. Serum/Plasma Biomarkers in Haematological Malignancies

    Human serum and plasma are widely used biofluid sources for proteomic analysis of haematological malignancies. The derivation of blood cancers from cells of the haematological system indicates serum and plasma as rich sources of blood cancer-associated biomarkers. Many blood-based protein biomarkers, such as lactate dehydrogenase and β2-microglobulin, have been identified in haematological malignancies (Table 2). However, they often serve as complementary markers of disease meaning invasive procedures such as bone marrow biopsies are required in addition to blood-based tests to confirm diagnosis, response to treatment, and relapse. Furthermore, with the approval of more targeted therapies for the treatment of blood cancers, such as venetoclax (BCL2 inhibitor), detecting specific molecular signatures to personalise therapeutic regimens is becoming increasingly important.
    Table 2. Current clinically used protein biomarkers in haematological malignancies.
    Biofluid Protein Type of Blood Cancer Technology Clinical Purpose References
    Serum Monoclonal immunoglobulin (M-protein) Multiple myeloma Serum protein electrophoresis immunofixation electrophoresis Diagnostic and monitoring disease [21]
    Free light chains (Bence Jones proteins) Multiple myeloma Immunoturbidimetric and immunonephelometric assays Diagnostic and monitoring of patients with light-chain disease. [22]
    Βeta 2-microglobulin Multiple myeloma Nephelometry immunoturbidimetry Prognostic [23][24][25][26][27][28][29][30]
    Acute leukaemia
    Chronic leukaemia
    Hodgkin’s lymphoma
    Non-Hodgkin’s lymphoma
    Lactate dehydrogenase Multiple myeloma Enzyme kinetics assay Prognostic [31][32][33][34][35]
    Acute leukaemia
    Chronic leukaemia
    Hodgkin’s lymphoma
    Non-Hodgkin’s lymphoma
    Uric acid Acute myeloid leukaemia Colorimetric enzyme assay Prognostic [36]
    Urine Monoclonal immunoglobulin (M-protein) Multiple myeloma Protein electrophoresis
    Immunofixation electrophoresis
    Diagnostic and monitoring of disease [37]
      Free light chains (Bence Jones proteins) Multiple myeloma Immunofixation electrophoresis
    Immunoturbidimetry
    Monitor disease progression and response to therapy [37]
    Cerebrospinal fluid Βeta 2-microglobulin Lymphoma Nephelometry Indicative of central nervous system (CNS) involvement [38]
    Leukaemia
    Many proteins have been found to be differentially expressed in the serum of patients with haematological malignancies compared to healthy controls. Recently, a study carried out by Chanukuppa et al. used a combination mass spectrometry, gel electrophoresis, and enzyme-linked immunosorbent assays (ELISAs) to identify and validate a panel of five serum proteins: haptoglobin; kininogen 1; transferrin; apolipoprotein A1; and the well-known MM marker, albumin, as potential diagnostic and prognostic biomarkers in MM [39]. Interestingly, a recent peptidomics study incorporating supervised neural network analyses identified a serum-based diagnostic MM model consisting of four peptides capable of distinguishing between MM disease states including healthy controls, newly diagnosed MM, and patients in complete remission, illustrating the potential of this model as a minimally invasive means of monitoring disease progression and treatment efficacy. The four peptides were found to be derived from dihydropyrimidinase-like 2, platelet factor 4, alpha-fetoprotein, and fibrinogen alpha [40]. A number of malignancies have been found to be associated with mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) and IDH2, including acute myeloid leukemia (AML) and myeloproliferative neoplasms [41][42][43]. The enzymes derived from these mutated genes have altered activity, producing 2-hydroxyglutarate (2-HG), an oncometabolite found to be increased in the serum of AML patients with IDH mutations and reduced following response to treatment. Monitoring serum 2-HG levels using liquid chromatography tandem mass spectrometry (LC–MS/MS) has been incorporated in various clinical trials to determine the efficacy of novel treatments in AML with IDH mutations [44]. The use of this technique has been reported to result in variable reference cut-off values due to the presence of two enantiomers. A recent study by Bories et al. used a chromatographic separation technique developed by Poinsignon et al. in order to establish individual reference values for each enantiomer to facilitate routine clinical use of serum 2-HG as a biomarker for disease monitoring in AML [45][46]. In acute lymphoblastic leukemia (ALL), various serum proteins have been identified in recent years as candidate biomarkers including S100A8, coagulation factor XIII subunit A, and a panel of 9 serum-derived glycoproteins [47][48][49]. Studies incorporating larger cohorts and clinically relevant workflows are required to bring “potential” and “candidate” serum biomarkers from benchtop to clinical use, a difficult task in certain cases due to low reproducibility, a lack of method standardisation, and difficulties translating the test used during discovery to a clinical-grade technology [50]. Studies focusing on the proteomic cargo of serum/plasma-derived extracellular vesicles in haematological malignancies have revealed interesting results, identifying proteins associated with drug resistance [51], survival, proliferation [52], and myelosuppression [53]. Blast-derived exosomes isolated from the sera of AML patients were found to contribute to immune suppression, in part by the inhibition of natural killer (NK) cell functions. Exosome-derived transforming growth factor-β1 contributes to NK cell suppression via a signalling cascade resulting in the downregulation of natural killer group 2 member D (NKG2D), a transmembrane receptor essential for the cytotoxicity of NK cells [54]. Incubation of neutralising antibodies targeting TGF-β with TGF-β+ AML exosomes followed by co-incubation with the NK cell line, NK-92, restored the cytotoxic activity of NK cells, illustrating exosome-derived TGF-β as a potential therapeutic target for the restoration of immune cell cytotoxicity in AML [55]. Efforts are being made by several research groups to improve current methods of CTC isolation and detection in MM. High numbers of circulating malignant plasma cells in the peripheral blood of the pre-malignant conditions, monoclonal gammopathy of un-determined significance (MGUS), and smouldering MM (SMM), as well as active MM, are associated with an increased likelihood of disease progression and a poor prognosis [56][57]. In addition to CTC enumeration, genomic and proteomic analysis of CTCs represents a unique opportunity for the molecular characterisation of these cells to guide personalised medicine by identifying biomarkers and therapeutic targets in a non-invasive, longitudinal manner [58].
    Cancer relapse is of foremost concern due to the high rate of recurrence among patients with haematological malignancies. Monitoring minimal/measurable residual disease (MRD) with high sensitivity is essential for the early detection of relapse in patients. Improving the sensitivity of blood-based MRD testing has been the central goal for many researchers in recent years to facilitate longitudinal sampling without subjecting the patient to numerous invasive procedures. Currently, clonoSEQ is the only FDA-approved next-generation sequencing (NGS)-based assay to detect MRD in bone marrow samples from acute lymphoblastic leukaemia (ALL) and MM patients and in bone marrow samples and peripheral blood from patients with chronic lymphocytic leukaemia [59][60][61]. Several studies have used mass spectrometry-based methods to assess MRD by detecting clonotypic tryptic peptides derived from monoclonal immunoglobulins in the serum of MM patients, demonstrating a high sensitivity and the ability to detect clonal Igs in the serum of MM patients deemed to be MRD-negative by multiparameter flow cytometry (MFC) [62][63]. The increase in the use of MS-based techniques in the evaluation of M-proteins in plasma cell disorders (PCDs) led the international myeloma working group (IMWG) to provide recommendations on the use of MS in PCDs, encouraging further research on MS-based techniques as a means of testing MRD in the peripheral blood of MM patients [64].

    2.5. Proteomics of Other Biofluids in Haematological Malignancies

    Proteomic analyses focused on saliva, bone marrow conditioned media, urine and cerebrospinal fluid in haematological malignancies are discussed in detail in the full version of this review article.

    The entry is from 10.3390/ijms22158021

    References

    1. Macklin, A.; Khan, S.; Kislinger, T. Recent advances in mass spectrometry based clinical proteomics: Applications to cancer research. Clin. Proteom. 2020, 17.
    2. Yang, X.-L.; Shi, Y.; Zhang, D.-D.; Xin, R.; Deng, J.; Wu, T.-M.; Wang, H.-M.; Wang, P.-Y.; Liu, J.-B.; Li, W.; et al. Quantitative proteomics characterization of cancer biomarkers and treatment. Mol. Ther.-Oncolytics 2021, 21, 255–263.
    3. Marrugo-Ramírez, J.; Mir, M.; Samitier, J. Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. Int. J. Mol. Sci. 2018, 19, 2877.
    4. Pietrowska, M.; Wlosowicz, A.; Gawin, M.; Widlak, P. MS-Based Proteomic Analysis of Serum and Plasma: Problem of High Abundant Components and Lights and Shadows of Albumin Removal. Adv. Exp. Med. Biol. 2019, 1073, 57–76.
    5. Yu, Z.; Kastenmüller, G.; He, Y.; Belcredi, P.; Möller, G.; Prehn, C.; Mendes, J.; Wahl, S.; Roemisch-Margl, W.; Ceglarek, U.; et al. Differences between Human Plasma and Serum Metabolite Profiles. PLoS ONE 2011, 6, e21230.
    6. O’Connell, G.C.; Alder, M.; Webel, A.R.; Moore, S.M. Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma. Bioanalysis 2019, 11, 2087–2094.
    7. O’Neal, W.K.; Anderson, W.; Basta, P.V.; Carretta, E.E.; Doerschuk, C.M.; Barr, R.G.; Bleecker, E.R.; Christenson, S.A.; Curtis, J.L.; Han, M.K.; et al. Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J. Transl. Med. 2014, 12, 9.
    8. Mannello, F. Serum or plasma samples? The “Cinderella” role of blood collection procedures: Preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diag-nostic trueness and leading to misinterpretation. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 611–614.
    9. Kim, H.S. Blood Glucose Measurement: Is Serum Equal to Plasma? Diabetes Metab. J. 2016, 40, 365–366.
    10. Ekdahl, K.N.; Norberg, D.; Bengtsson, A.A.; Sturfelt, G.; Nilsson, U.R.; Nilsson, B. Use of Serum or Buffer-Changed EDTA-Plasma in a Rapid, Inexpensive, and Easy-To-Perform Hemolytic Complement Assay for Differential Diagnosis of Systemic Lupus Erythematosus and Monitoring of Patients with the Disease. Clin. Vaccine Immunol. 2007, 14, 549–555.
    11. Chan, K.C.; Lucas, D.A.; Hise, D.; Schaefer, C.F.; Xiao, Z.; Janini, G.M.; Buetow, K.H.; Issaq, H.J.; Veenstra, T.D.; Conrads, T.P. Analysis of the human serum proteome. Clin. Proteom. 2004, 1, 101–225.
    12. Pieper, R.; Gatlin, C.L.; Makusky, A.J.; Russo, P.S.; Schatz, C.R.; Miller, S.S.; Su, Q.; McGrath, A.M.; Estock, M.A.; Parmar, P.P.; et al. The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3, 1345–1364.
    13. Veenstra, T.D.; Conrads, T.P.; Hood, B.L.; Avellino, A.M.; Ellenbogen, R.G.; Morrison, R.S. Biomarkers: Mining the Biofluid Proteome. Mol. Cell. Proteom. 2005, 4, 409–418.
    14. Anderson, N.L.; Anderson, N.G. The Human Plasma Proteome: History, character, and diagnostic prospects. Mol. Cell. Proteom. 2002, 1, 845–867.
    15. Lee, P.Y.; Osman, J.; Low, T.Y.; Jamal, R. Plasma/serum proteomics: Depletion strategies for reducing high-abundance proteins for biomarker discovery. Bioanalysis 2019, 11, 1799–1812.
    16. Duan, X.; Yarmush, D.; Berthiaume, F.; Jayaraman, A.; Yarmush, M.L. Immunodepletion of albumin for two-dimensional gel detection of new mouse acute-phase protein and other plasma proteins. Proteomics 2005, 5, 3991–4000.
    17. Tsang, J.C.; Lo, Y.D. Circulating nucleic acids in plasma/serum. Pathology 2007, 39, 197–207.
    18. Dementeva, N.; Kokova, D.; Mayboroda, O. Current Methods of the Circulating Tumor Cells (CTC) Analysis: A Brief Overview. Curr. Pharm. Des. 2017, 23, 4726–4728.
    19. Yu, S.; Cao, H.; Shen, B.; Feng, J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget 2015, 6, 37151–37168.
    20. Hocking, J.; Mithraprabhu, S.; Kalff, A.; Spencer, A. Liquid biopsies for liquid tumors: Emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol. Med. 2016, 13, 215–225.
    21. Willrich, M.A.; Murray, D.L.; Kyle, R.A. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin. Biochem. 2018, 51, 38–47.
    22. Messiaen, M.A.-S.; De Sloovere, M.M.M.W.; Claus, P.-E.; Vercammen, M.; Van Hoovels, M.L.; Heylen, M.O.; Debrabandere, M.J.; Vanpoucke, M.H.; De Smet, D. Performance Evaluation of Serum Free Light Chain Analysis: Nephelometry vs Turbidimetry, Monoclonal vs Polyclonal Reagents. Am. J. Clin. Pathol. 2017, 147, 611–622.
    23. Bernard, A.M.; Vyskocil, A.; Lauwerys, R.R. Determination of beta 2-microglobulin in human urine and serum by latex im-munoassay. Clin. Chem. 1981, 27, 832–837.
    24. Lievens, M.M.; Woestyn, S.; De Nayer, P.; Collet-Cassart, D. Measurement of ß2-Microglobulin in Serum by a Particle-Enhanced Nephelometric Immunoassay. Clin. Chem. Lab. Med. 1991, 29, 401–404.
    25. Chng, W.J.; on behalf of the International Myeloma Working Group; Dispenzieri, A.; Chim, C.; Fonseca, R.; Goldschmidt, H.; Lentzsch, S.; Munshi, N.C.; Palumbo, A.; Miguel, J.S.; et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2013, 28, 269–277.
    26. Tsimberidou, A.M.; Kantarjian, H.M.; Wen, S.; O’Brien, S.; Cortes, J.; Wierda, W.G.; Koller, C.; Pierce, S.; Brandt, M.; Freireich, E.J.; et al. The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients. Clin. Cancer Res. 2008, 14, 721–730.
    27. Kantarjian, H.M.; Smith, T.; Estey, E.; Polyzos, A.; O’Brien, S.; Pierce, S.; Beran, M.; Feldman, E.; Keating, M.J. Prognostic significance of elevated serum β2-microglobulin levels in adult acute lymphocytic leukemia. Am. J. Med. 1992, 93, 599–604.
    28. Rodriguez, J.; Cortes, J.; Talpaz, M.; O’Brien, S.; Smith, T.L.; Rios, M.B.; Kantarjian, H. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin. Cancer Res. 2000, 6, 147–152.
    29. Wu, L.; Wang, T.; Gui, W.; Lin, H.; Xie, K.; Wang, H.; Gao, T.; Zhang, X.; Liu, L.; Han, T.; et al. Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma. Oncology 2014, 87, 40–47.
    30. Vassilakopoulos, T.P.; Nadali, G.; Angelopoulou, M.K.; Siakantaris, M.P.; Dimopoulou, M.N.; Kontopidou, F.N.; Karkantaris, C.; Kokoris, S.I.; Kyrtsonis, M.C.; Tsaftaridis, P.; et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin’s lymphoma. Haematologica 2002, 87, 701–708; discussion 708.
    31. Teke, H.; Başak, M.; Teke, D.; Kanbay, M. Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report. Turk. J. Haematol. 2014, 31, 84–87.
    32. D’Angelo, G.; Giardini, C.; Calvano, D. Clinical significance of the determination of lactate dehydrogenase in acute leukemia and non-Hodgkin’s lymphoma. Minerva Med. 1989, 80, 549–552.
    33. Patel, P.; Adhvaryu, S.G.; Balar, D.B. Serum lactate dehydrogenase and its isoenzymes in leukemia patients: Possible role in diagnosis and treatment monitoring. Neoplasma 1994, 41, 55–59.
    34. Endrizzi, L.; Fiorentino, M.V.; Salvagno, L.; Segati, R.; Pappagallo, G.L.; Fosser, V. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin’s lymphoma. Eur. J. Cancer Clin. Oncol. 1982, 18, 945–949.
    35. García, R.; Hernández, J.; Caballero; González, M.; Galende, J.; Del Cañizo, M.; Vázquez, L.; Miguel, J.S. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br. J. Cancer 1993, 68, 1227–1231.
    36. Yamauchi, T.; Negoro, E.; Lee, S.; Takai, M.; Matsuda, Y.; Takagi, K.; Kishi, S.; Tai, K.; Hosono, N.; Tasaki, T.; et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013, 33, 3947–3951.
    37. Singh, G. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. J. Appl. Lab. Med. 2020, 5, 1358–1371.
    38. Jeffery, G.M.; Frampton, C.M.; Legge, H.M.; Hart, D.N.J.; Jeffery, M.G. Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990, 22, 20–23.
    39. Chanukuppa, V.; Taware, R.; Taunk, K.; Chatterjee, T.; Sharma, S.; Somasundaram, V.; Rashid, F.; Malakar, D.; Santra, M.K.; Rapole, S. Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples. Front. Oncol. 2021, 10.
    40. Bai, J.; Yang, Y.; Wang, J.; Zhang, L.; Wang, F.; He, A. Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma. Clin. Proteom. 2019, 16, 17.
    41. Yen, K.E.; Bittinger, M.A.; Su, S.M.; Fantin, V.R. Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 2010, 29, 6409–6417.
    42. Paschka, P.; Schlenk, R.F.; Gaidzik, V.I.; Habdank, M.; Krönke, J.; Bullinger, L.; Späth, D.; Kayser, S.; Zucknick, M.; Götze, K.; et al. IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication. J. Clin. Oncol. 2010, 28, 3636–3643.
    43. Tefferi, A.; Lasho, T.L.; Abdel-Wahab, O.; Guglielmelli, P.; Patel, J.; Caramazza, D.; Pieri, L.; Finke, C.M.; Kilpivaara, O.; Wadleigh, M.; et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24, 1302–1309.
    44. Heuser, M.; Palmisiano, N.; Mantzaris, I.; Mims, A.; DiNardo, C.; Silverman, L.R.; Wang, E.S.; Fiedler, W.; Baldus, C.; Schwind, S.; et al. Safety and efficacy of BAY1436032 in IDH1-mutant AML: Phase I study results. Leukemia 2020, 34, 2903–2913.
    45. Bories, P.-N.; Nakib, S.; Cynober, L.; Alary, A.S.; Coude, M.-M.; Chevillon, F.; Tamburini, J.; Birsen, R.; Kosmider, O.; Bouscary, D. Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia. Clin. Chem. Lab. Med. 2018, 57, e57–e59.
    46. Poinsignon, V.; Mercier, L.; Nakabayashi, K.; David, M.; Lalli, A.; Penard-Lacronique, V.; Quivoron, C.; Saada, V.; DE Botton, S.; Broutin, S.; et al. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J. Chromatogr. B 2016, 1022, 290–297.
    47. Yu, R.; Zhang, J.; Zang, Y.; Zeng, L.; Zuo, W.; Bai, Y.; Liu, Y.; Sun, K.; Liu, Y. iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia. Cancer Manag. Res. 2019, 11, 7047–7063.
    48. Kárai, B.; Gyurina, K.; Ujfalusi, A.; Sędek, Ł.; Barna, G.; Jáksó, P.; Svec, P.; Szánthó, E.; Nagy, A.C.; Müller, J.; et al. Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia. Cancers 2020, 12, 2264.
    49. Cavalcante, M.D.S.; Romero, J.C.T.; Lobo, M.D.P.; Moreno, F.B.M.B.; Bezerra, L.P.; Lima, D.S.; Matos, J.C.; Moreira, R.D.A.; Monteiro-Moreira, A.C.D.O. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia. Biomark. Res. 2016, 4, 1–8.
    50. Kearney, P.; Boniface, J.J.; Price, N.; Hood, L. The building blocks of successful translation of proteomics to the clinic. Curr. Opin. Biotechnol. 2018, 51, 123–129.
    51. Harshman, S.; Canella, A.; Ciarlariello, P.D.; Agarwal, K.; Branson, O.E.; Rocci, A.; Cordero, H.; Phelps, M.A.; Hade, E.; Dubovsky, J.A.; et al. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J. Proteom. 2016, 136, 89–98.
    52. Prieto, D.; Sotelo, N.S.; Seija, N.; Sernbo, S.; Abreu, C.; Durán, R.; Gil, M.; Sicco, E.; Irigoin, V.; Oliver, A.; et al. S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression. Blood 2017, 130, 777–788.
    53. Namburi, S.; Broxmeyer, H.E.; Hong, C.-S.; Whiteside, T.L.; Boyiadzis, M. DPP4+ exosomes in AML patients’ plasma suppress proliferation of hematopoietic progenitor cells. Leukemia 2020, 35, 1925–1932.
    54. Szczepanski, M.J.; Szajnik, M.; Welsh, A.; Whiteside, T.L.; Boyiadzis, M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011, 96, 1302–1309.
    55. Hong, C.-S.; Sharma, P.; Yerneni, S.S.; Simms, P.; Jackson, E.K.; Whiteside, T.L.; Boyiadzis, M. Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia. Sci. Rep. 2017, 7, 4684.
    56. Gonsalves, W.I.; Rajkumar, S.V.; Dispenzieri, A.; Dingli, D.; Timm, M.M.; Morice, W.G.; Lacy, M.Q.; Buadi, F.K.; Go, R.S.; Leung, N.; et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 2016, 31, 130–135.
    57. Flores-Montero, J.; Sanoja-Flores, L.; Paiva, B.D.L.; Puig, N.; García-Sánchez, O.; Böttcher, S.; Van Der Velden, V.H.J.; Pérez-Morán, J.-J.; Vidriales, M.-B.; Garcia-Sanz, R.; et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017, 31, 2094–2103.
    58. Zhang, L.; Beasley, S.; Prigozhina, N.L.; Higgins, R.; Ikeda, S.; Lee, F.Y.; Marrinucci, D.; Jia, S. Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma. J. Circ. Biomarkers 2016, 5, 10.
    59. Costa, L.J.; Derman, B.A.; Bal, S.; Sidana, S.; Chhabra, S.; Silbermann, R.; Ye, J.C.; Cook, G.; Cornell, R.F.; Holstein, S.A.; et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 2020, 35, 18–30.
    60. Kumar, S.; Paiva, B.D.L.; Anderson, K.C.; Durie, B.; Landgren, O.; Moreau, P.; Munshi, N.; Lonial, S.; Bladé, J.; Mateos, M.-V.; et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17, e328–e346.
    61. Ching, T.; Duncan, M.E.; Newman-Eerkes, T.; McWhorter, M.M.E.; Tracy, J.M.; Steen, M.S.; Brown, R.P.; Venkatasubbarao, S.; Akers, N.K.; Vignali, M.; et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 2020, 20, 612.
    62. Bergen, H.R., 3rd; Dasari, S.; Dispenzieri, A.; Mills, J.R.; Ramirez-Alvarado, M.; Tschumper, R.C.; Jelinek, D.F.; Barnidge, D.R.; Murray, D.L. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. Clin. Chem. 2016, 62, 243–251.
    63. Martins, C.O.; Huet, S.; Yi, S.S.; Ritorto, M.S.; Landgren, O.; Dogan, A.; Chapman, J.R. Mass Spectrometry–Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. J. Mol. Diagn. 2020, 22, 901–911.
    64. Murray, D.L.; Puig, N.; Kristinsson, S.; Usmani, S.Z.; Dispenzieri, A.; Bianchi, G.; Kumar, S.; Chng, W.J.; Hajek, R.; Paiva, B.; et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021, 11, 24.
    More